Ms CHAU WEI LING1, A/Prof KAMAL SUD2,3,4,5,6, A/Prof VINCENT W. LEE6,7, Dr CONNIE VAN1, Prof GREGORY M. PETERSON8,9, A/Prof SYED TABISH RAZI ZAIDI10, Dr RAHUL P. PATEL8, Dr RONALD L. CASTELINO1,11
1The University of Sydney, Sydney, Australia, 2Department of Renal Medicine, Nepean Hospital, Sydney, Australia , 3Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia, 4Peritoneal Dialysis Unit, Regional Dialysis Centre, Blacktown Hospital, Sydney, Australia, 5Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Peritoneal Dialysis Working Group, Adelaide, Australia, 6Departments of Renal Medicine, Blacktown and Westmead Hospitals, Sydney, Australia, 7Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia, 8School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Australia, 9Faculty of Health, University of Canberra , Bruce, Australia, 10Professional Services Unit, HPS Pharmacies, EBOS Group, Docklands, Australia, 11Department of Pharmacy, Blacktown Hospital, Blacktown, Australia
Aim
Our study aims to examine the incidence, treatment, and outcomes of peritonitis due to Rothia spp. in patients on peritoneal dialysis (PD) in Australia and New Zealand.
Background
PD-associated peritonitis remains a severe complication of PD. Although PD-associated peritonitis due to Rothia spp. is rare, the treatment recommendations and outcomes are uncertain.
Methods
Using data from the Australia and New Zealand Dialysis and Transplant Registry, all PD patients who developed peritonitis due to Rothia spp. between 2011 to 2020, were included and analysed.
Results
Of the 20,653 episodes of peritonitis, only 28 (0.14%) episodes were caused by Rothia spp. Of these, 17 (60.7%) episodes were caused by Rothia mucilaginosa, 5 (17.9%) episodes by Rothia dentacariosa. In 6 (21.4%) episodes, the species was not specified. Twenty-two episodes were treated with a single antibiotic regimen [vancomycin (57.1%), cefazolin (14.3%),amoxicillin (3.6%) and amoxicillin/clavulanate acid (3.6%)], while 6 episodes were treated with a combination antibiotic regimen [ceftazidime/vancomycin (10.7%), cefazolin/gentamicin (3.5%), flucloxacillin/ciprofloxacin (3.5%), and gentamicin/vancomycin (3.5%)]. The median (IQR) duration of antibiotic therapy was 2.1 (1.9-2.9) weeks. All peritonitis episodes caused by Rothia mucilaginosa peritonitis had complete cure, while episodes caused by Rothia dentacariosa and where Rothia spp. was not specified had complete cure in 80% and 33% of the cases, respectively. While no deaths within 30-days of developing peritonitis were reported, catheter removal was reported in 2 (7.1%).
Conclusions
PD-associated peritonitis due to Rothia spp. is uncommon and associated with relatively good outcomes.
Biography:
Bio to come